These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 12724928)
1. A comparative study of four serological tumor markers for the detection of breast cancer. Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928 [TBL] [Abstract][Full Text] [Related]
2. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478 [TBL] [Abstract][Full Text] [Related]
3. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573 [TBL] [Abstract][Full Text] [Related]
4. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. van Dalen A; Kessler AC Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058 [TBL] [Abstract][Full Text] [Related]
5. Comparison of alpha-fetoprotein with some other tumour markers in Malaysians with hepatocellular carcinoma. Lopez JB; Balasegaram M; Timor J; Thambyrajah V Malays J Pathol; 1997 Jun; 19(1):53-8. PubMed ID: 10879242 [TBL] [Abstract][Full Text] [Related]
6. [Tumor markers in the diagnosis and prognosis of breast cancer]. Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917 [TBL] [Abstract][Full Text] [Related]
7. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer. Sütterlin M; Bussen S; Trott S; Caffier H Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196 [TBL] [Abstract][Full Text] [Related]
9. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806 [TBL] [Abstract][Full Text] [Related]
10. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation. Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728 [TBL] [Abstract][Full Text] [Related]
11. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals. Erden G; Barazi AO; Tezcan G; Yildirimkaya MM Scand J Clin Lab Invest; 2008; 68(3):212-8. PubMed ID: 17926198 [TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Zheng H; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113 [TBL] [Abstract][Full Text] [Related]
13. The serum tumor marker M3/M21 in the follow-up of breast cancer patients. Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765 [TBL] [Abstract][Full Text] [Related]
14. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191 [TBL] [Abstract][Full Text] [Related]
15. Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients. Jäger W; Eibner K; Löffler B; Gleixner S; Krämer S Anticancer Res; 2000; 20(6D):5179-82. PubMed ID: 11326691 [TBL] [Abstract][Full Text] [Related]
16. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813 [TBL] [Abstract][Full Text] [Related]
17. Influence of cardiopulmonary resuscitation on levels of tumour markers. Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121 [TBL] [Abstract][Full Text] [Related]
18. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851 [TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer. Eskelinen M; Tikanoja S; Brown J Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995 [TBL] [Abstract][Full Text] [Related]
20. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Ławicki S; Szmitkowski M; Wojtukiewicz M Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]